Effect Of Ambroxol Hydrochlorided On Clinical Efficacy And Serum Hs-CRP,PCT And CPIS Levels In Patients With Acute COPD And Pulmonary Infection

Objective:To investigate the clinical efficacy of ambroxol hydrochloride in the treatment of chronic obstructive pulmonary disease(COPD)with acute pulmonary infection,and to analyze the clinical efficacy of ambroxol hydrochloride injection in patients with acute COPD with pulmonary infection and serum high-sensitivity C-reactive protein Effects of(hs-CRP),procalcitonin(PCT),and clinical lung infection score(CPIS).Methods:Eighty patients with COPD and acute lung infection who were treated in our hospital from May 2016 to May 2018 were enrolled.The patients were divided into observation group and control group according to the random number table method,40 cases each.The patients in the control group were treated with conventional therapy.The patients in the observation group were treated with ambroxol hydrochloride on the basis of the treatment of the control group.The course of treatment was 1 week.All patients were improved lung function,serum inflammatory factors,symptom evaluation and lymphocyte count at the time of admission and after treatment.The total effective rate and clinical symptom improvement time of the two groups were compared,and the lung function indexes of the two groups before and after treatment were compared,serum inflammatory factor levels,lymphocyte subsets,and lung infection score differences.Results:The total effective rate of the treatment group was 97.50%,and the total effective rate of the control group was 77.50%.The total effective rate of the observation group was significantly higher than that of the control group,and the difference was statistically significant(?~2=5.600,P=0.018).The improvement time of cough and cough in the observation group(5.68±1.09)was significantly shorter than that in the control group(7.03±1.35).The difference between the two groups was statistically significant(t=5.600,P=0.018).The observation group had improved chest tightness and shortness of breath(3.23±1.07)was significantly shorter than the control group(4.07±1.18),the difference between the groups was statistically significant(t=3.335,P=0.001);the improvement of lung voice in the observation group was significantly shorter than(5.62±1.56).In the control group(7.60±1.71),the difference between the groups was statistically significant(t=5.410,P=0.000).There was no significant difference in the levels of FEV1 and FEV1/FVC between the two groups before treatment(P>0.05).After treatment with different regimens,the FEV1 of the two groups were significantly higher than that before treatment.The levels of FEV1/FVC were also significantly higher than those before treatment,and the differences were statistically significant(P<0.05).The post-FEV1 level was significantly higher than that of the control group.The levels of FEV1/FVC were significantly higher than those of the control group.The difference between the two groups was statistically significant(P<0.05).There was no significant difference in serum hs-CRP,PCT and IL-6 levels between the two groups before treatment(P>0.05).After treatment with different regimens,serum hs-CRP,PCT,IL-6 levels in the two groups were significantly lower than before treatment,and there were significant differences between the two groups(P<0.05).The levels of hs-CRP,PCT and IL-6 were significantly lower than those of the control group,and the differences between the groups were statistically significant(P<0.05).There was no significant difference in the levels of CD4~+T,CD8~+T and CD4~+T/CD8~+T between the two groups before treatment(P>0.05).After treatment with different regimens,the levels of CD4~+T and CD4~+T/CD8~+T in the two groups were significantly higher than those before treatment.The level of CD8~+T was significantly lower than that before treatment.The difference between the two groups was statistically significant(P<0.05);and the levels of CD4~+T and CD4~+T/CD8~+T in the observation group were significantly higher than those in the control group,and the level of CD8+T was significantly lower than that in the control group.The difference between the groups was statistically significant(P<0.05).There was no significant difference in APACHE II and CPIS scores between the two groups before treatment(P>0.05).After treatment with different regimens,the APACHE II and CPIS scores of the two groups were significantly lower than before treatment,and the differences were statistically significant(P<0.05).The APACHE II and CPIS scores of the observation group were significantly improved after treatment.Compared with the control group,the difference between the groups was statistically significant(P<0.05).Conclusion:Ambroxol hydrochloride can effectively improve the therapeutic effect of basic treatment for patients with COPD complicated with acute lung infection,and can further improve the clinical symptoms of patients,improve lung function,serum inflammatory factor levels and lymphocyte subsets,and reduce lung infection scores.It is worth promoting in clinical application.